137 related articles for article (PubMed ID: 28675691)
1. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma.
Weyand AC; Mody RJ; Rabah RM; Opipari VP
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28675691
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
3. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
[TBL] [Abstract][Full Text] [Related]
4. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA; Joseph J; Hwu WJ
Discov Med; 2018 Jan; 25(135):31-40. PubMed ID: 29466692
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
6. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
Gangadhar TC; Schuchter LM
JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
[No Abstract] [Full Text] [Related]
7. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
8. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
Singh P; Wolfe SP; Alloo A; Gottesman SP
J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
11. Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.
Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Iizuka A; Nonomura C; Ohshima K; Urakami K; Kusuhara M; Nagashima T; Sugino T; Yamaguchi K; Akiyama Y
J Dermatol; 2017 Oct; 44(10):1156-1159. PubMed ID: 28452169
[TBL] [Abstract][Full Text] [Related]
12. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.
Chambon F; Osdoit S; Bagny K; Moro A; Nguyen J; RĂ©guerre Y
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988442
[TBL] [Abstract][Full Text] [Related]
13. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
14. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
15. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
16. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
17. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
[TBL] [Abstract][Full Text] [Related]
19. PD-1, CTLA-4 Point to Drug Response.
Cancer Discov; 2016 Nov; 6(11):1201. PubMed ID: 27655434
[TBL] [Abstract][Full Text] [Related]
20. PD-1 inhibitor becomes "breakthrough therapy".
Cancer Discov; 2013 Jul; 3(7):OF14. PubMed ID: 23847357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]